ISRG's Ion Platform: A Major Growth Engine in Lung Cancer Care?
ISRG's Ion platform saw 39% procedure growth in Q1, with new clinical data strengthening its role in lung cancer diagnosis.
ISRG - Intuitive Surgical, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$622.60
DETAILS
HIGH:
$750.00
LOW:
$525.00
MEDIAN:
$618.00
CONSENSUS:
$622.60
UPSIDE:
42.11%
Stock News
3 Medical Instrument Stocks Exploring GenAI to Tackle Industry Woes
GenAI is reshaping medical instruments as Electromed, Globus Medical and Intuitive Surgical navigate M&A and market pressures.
Why Is Intuitive Surgical (ISRG) Down 7.2% Since Last Earnings Report?
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock?
2 Most Compelling Stocks to Buy for Long‑Term Investors Right Now
It'd be a mistake to overlook these stocks, despite their recent challenges.
ISRG's SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
Intuitive Surgical's ISRG single-port (SP) platform emerges as one of its most intriguing long-term growth opportunities, though the key question remains whether it can unlock incremental total addressable market (TAM) or simply serve as a substitution within existing robotic procedures.
Intuitive Announces Innovations to Advance Quintuple Aim
Latest innovations include enhanced telecollaboration capabilities, extended uses for Force Feedback technology, and advancements in product and instrument reliability and security Latest innovations include enhanced telecollaboration capabilities, extended uses for Force Feedback technology, and advancements in product and instrument reliability and security
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
Forget Tesla. The Robotics Company Actually Shipping Revenue Has a $22 Billion Backlog and Nobody Is Talking About It
Everyone is still glued to Tesla (NASDAQ:TSLA | TSLA Price Prediction) because a Q1 earnings beat, the robotaxi pitch, and the Optimus humanoid tease have convinced retail traders the autonomy story finally pays off this year.
Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Surgical Robotics Meets AI: Intuitive Surgical, Medtronic, and Stryker Are the Sleeper Plays of the Healthcare Boom
Surgical robotics is quietly becoming an artificial intelligence story. Every robotic procedure generates structured video, kinematic, and outcomes data that platforms feed back into surgeon training, intraoperative guidance, and predictive analytics.
My Top 3 Healthcare Stocks for May 2026
Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.
Can ISRG's da Vinci 5 Momentum Sustain Procedure and Utilization Gains?
Intuitive Surgical's ISRG da Vinci 5 platform is rapidly emerging as a key growth engine, reinforcing both procedure momentum and utilization gains in the first quarter of 2026. Management highlighted that da Vinci procedures grew 16% year over year, while overall system utilization increased 4%, reflecting stronger throughput and expanding surgeon engagement.
Intuitive Surgical Trades Near 2-Year Low: Is $600 Within Reach?
ISRG nears a key support level after a 23.7% YTD drop, but strong da Vinci 5 adoption and procedure growth may fuel a rebound.
After Plunging 8.5% in 4 Weeks, Here's Why the Trend Might Reverse for Intuitive Surgical (ISRG)
The heavy selling pressure might have exhausted for Intuitive Surgical (ISRG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is Intuitive Surgical Inc (ISRG) a Bargain After 6.7% Drop? GF Value Says Undervalued
On May 11, 2026, Intuitive Surgical Inc (ISRG) shares fell 6.7% to $420.06. This decline comes amid a challenging year for the stock, which has experienced a ye
Intuitive Surgical's Moat Is Getting Stronger -- Is This the Closest Thing to a 'Forever' Stock?
Many investors understandably have doubts about the company right now.
Looking for a Growth Stock? 3 Reasons Why Intuitive Surgical (ISRG) is a Solid Choice
Intuitive Surgical (ISRG) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Brokers Suggest Investing in Intuitive Surgical (ISRG): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
ISRG DCF Analysis: Intrinsic Value $196 vs Price $450
On May 11, 2026, we present a detailed DCF analysis for Intuitive Surgical Inc (ISRG). The company has experienced a challenging price performance, with a year-
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.
Price Targets
Intuitive Surgical price target lowered to $651 from $712 at Barclays
$651.00
(was $483.62)
Barclays
Intuitive Surgical price target lowered to $580 from $650 at Truist
$580.00
(was $472.02)
Truist Financial
Intuitive Surgical price target lowered to $525 from $575 at Mizuho
$525.00
(was $450.47)
Mizuho Securities
Intuitive Surgical price target lowered to $570 from $600 at UBS
$570.00
(was $491.00)
UBS
Intuitive Surgical price target raised to $712 from $686 at Barclays
$712.00
(was $523.99)
Barclays
Intuitive Surgical price target lowered to $550 from $580 at Evercore ISI
$550.00
(was $523.60)
Vijay Kumar
·
Evercore ISI
Intuitive Surgical price target raised to $620 from $610 at Piper Sandler
$620.00
(was $525.81)
Piper Sandler
Intuitive Surgical price target raised to $750 from $740 at Bernstein
$750.00
(was $525.81)
Bernstein
Intuitive Surgical price target raised to $740 from $700 at Bernstein
$740.00
(was $585.08)
Bernstein
Intuitive Surgical price target raised to $714 from $621 at Goldman Sachs
$714.00
(was $585.08)
Goldman Sachs
Intuitive Surgical price target raised to $616 from $589 at BTIG
$616.00
(was $592.85)
BTIG
Intuitive Surgical price target raised to $686 from $635 at Barclays
$686.00
(was $592.85)
Barclays
Intuitive Surgical price target raised to $580 from $540 at Evercore ISI
$580.00
(was $565.96)
Evercore ISI
Intuitive Surgical price target raised to $650 from $620 at Truist
$650.00
(was $565.57)
Truist Financial
Intuitive Surgical price target raised to $650 from $625 at RBC Capital
$650.00
(was $554.58)
Shagun Singh
·
RBC Capital
Intuitive Surgical price target raised to $600 from $585 at UBS
$600.00
(was $527.03)
UBS
Intuitive Surgical price target raised to $575 from $520 at Mizuho
$575.00
(was $462.74)
Anthony Petrone
·
Mizuho Securities
Intuitive Surgical (ISRG) PT Raised to $620 at Truist Securities
$620.00
(was $462.74)
Richard Newitter
·
Truist Financial
Intuitive Surgical price target raised to $625 from $615 at RBC Capital
$625.00
(was $462.74)
RBC Capital
Intuitive Surgical price target raised to $603 from $592 at Raymond James
$603.00
(was $462.74)
Raymond James